NL-OMON43609已完成3 期
Varenicline, a partial nicotinic receptor agonist, for the treatment of excessive daytime sleepiness in Parkinson*s disease: a placebo-controlled cross-over study - Vareniciline for excessive daytime sleepiness in Parkinson*s disease
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-idiopathic Parkinson's Disease (PD) according to criteria UK PD Society Brain Bank
- •-receiving stable PD medications for at least 4 weeks before and throughout the study
- •-excessive daytime sleepiness (defined by a score of >10 on the Epworth Sleeping Scale)
排除标准
- •- patients receiving medications with known central depressant effects
- •- dementia
- •- depression
- •- known sleep apnea or narcolepsy
- •- current smoking
- •- contra-indications for treatment with varenicline (psychiatric illness, renal failure, ischemic cardial disease, stroke, insuline-dependent diabetes)
研究者
相似试验
进行中（未招募）
1 期
Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s DiseaseIdiopathic Parkinson's diseaseMedDRA version: 18.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-001530-34-NLVU University Medical Center32
已完成
不适用
Varenicline for the Treatment of Smokeless TobaccoNicotine DependenceNCT00813917Mayo Clinic76
进行中（未招募）
1 期
Varenicline for long-term nicotine replacement therapy (NRT) usersA double blind, placebo controlled trial - Long-term NRT:vareniclineEUCTR2008-006426-34-DKPulmonary dept. Gentofte Hospital200
已完成
2 期
The effect of varenicline on depression in smokersmajor depressive disorder.Major depressive disorder, single episodeIRCT20190308042972N1Yazd University of Medical Sciences60
已完成
3 期
Tailoring Varenicline to Individual Needs (TVIN Study)Tobacco DependenceSmoking CessationNCT01206010Queen Mary University of London200